Abby Hardy, Author at BioTuesdays

Developments

Evofem Biosciences enrolls first patient in Phase 3 STD prevention trial

Evofem Biosciences (NASDAQ:EVFM) enrolled the first patient in its Phase 3 trial evaluating EVO100 for the prevention of urogenital chlamydia and gonorrhea in women. The trial, called EVOGUARD, will enroll 1,730 women...

October 20, 2020

Developments

Selecta gets FDA rare pediatric disease designation for methylmalonic acidemia gene therapy

Selecta Biosciences’ (NASDAQ:SELB) MMA-101 received FDA rare pediatric disease designation for the treatment of methylmalonic acidemia (MMA). MMA is caused by a mutation in the methylmalonyl-CoA mutase gene, which...

October 20, 2020

Feature

Novamind building infrastructure for regulated psychedelic industry

Closely-held Novamind is building the infrastructure required to facilitate safe, legal and medically-supervised psychedelic-assisted therapy. “We saw an opportunity to build a sustainable business in a market that’s...

October 20, 2020

Developments

Anavex reports positive results from Phase 2 Parkinson’s disease trial

Anavex Life Sciences (NASDAQ:AVXL) reported positive results from its Phase 2 study evaluating ANAVEX2-73 for the treatment of Parkinson’s disease dementia. The proof-of-concept study enrolled 132 patients who received...

October 15, 2020

Executive Moves

iBio appoints accomplished financial executive, Gary Sender, to board

Gary Sender iBio (NYSE AMERICAN:IBIO) appointed senior financial executive, Gary Sender, as a director and a member of the board’s compensation committee. In addition, Mr. Sender was appointed chair of iBio’s audit...

October 15, 2020

Developments

Titan Pharma to focus on ProNeura-based product development

Titan Pharmaceuticals (NASDAQ:TTNP) reported that it will discontinue U.S. Probuphine sales and wind down commercialization activities as it restructures to focus on ProNeura-based product development. “Marketing of...

October 15, 2020

Executive Moves

iBio appoints senior biopharma executive, Dr. Alexandra Kropotova, to board

Alexandra Kropotova iBio (NYSE AMERICAN:IBIO) appointed senior biopharma executive, Dr. Alexandra Kropotova, as a director and a member of the board’s new science and technology committee. Dr. Kropotova has expertise in...

October 15, 2020

Executive Moves

iBio appoints renowned biopharma executive, Dr. Linda Armstrong, to board

iBio (NYSE AMERICAN:IBIO) appointed Dr. Linda Armstrong, a renowned biopharma executive, as a director and a member of the board’s new science and technology committee. “We are pleased to welcome Dr. Armstrong to our...

October 14, 2020

Developments

Taysha gets FDA rare pediatric and orphan drug designations for Rett syndrome

Taysha Gene Therapies (NASDAQ:TSHA) received FDA rare pediatric and orphan drug designations for TSHA-102 for the treatment of Rett syndrome. Rett syndrome is a genetic neurodevelopmental disorder characterized by...

October 14, 2020

Developments

Evelo doses first patient in Phase 2 psoriasis study

Evelo Biosciences (NASDAQ:EVLO) dosed the first patient in its Phase 2 study evaluating EDP1815 for the treatment of mild-to-moderate psoriasis. The placebo-controlled study will enroll 225 patients to evaluate three...

October 13, 2020

Author - Abby Hardy

Evofem Biosciences enrolls first patient in Phase 3 STD prevention trial

Selecta gets FDA rare pediatric disease designation for methylmalonic acidemia gene therapy

Novamind building infrastructure for regulated psychedelic industry

Anavex reports positive results from Phase 2 Parkinson’s disease trial

iBio appoints accomplished financial executive, Gary Sender, to board

Titan Pharma to focus on ProNeura-based product development

iBio appoints senior biopharma executive, Dr. Alexandra Kropotova, to board

iBio appoints renowned biopharma executive, Dr. Linda Armstrong, to board

Taysha gets FDA rare pediatric and orphan drug designations for Rett syndrome

Evelo doses first patient in Phase 2 psoriasis study

General

More